Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?
Infectious disease could fuel Eli Lilly's next growth phase.
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
June 9 (Reuters) - British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio. The all-cash deal values Nuvalent ...
FiercePharma
The Oral GLP-1 Tracker: Week 1 of Lilly's Foundayo launch
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...